Monopar Therapeutics
Canonical company identity and public leadership record.
- Source reported. 23 claims from 3 sources.
- Not claimed by the company.
- Eval: not assessed.
- Chair
- Not published
- Board
- 6 directorsAlpha calculation. Published seats
- Independence
- 5 of 6Alpha calculation
- Committees
- 6
- Evidence
- 3 sources23 published claims
- Open conflicts
- 0None open
Leadership
1 claim| Person | Role | Since | Status | Evidence |
|---|---|---|---|---|
| Chandler D. Robinson | CEO, Co-Founder and Director | Current | Source reportedE3 |
Board
6 claims| Director | Status | Since | Committees | Evidence |
|---|---|---|---|---|
| Arthur J. Klausner, MBA | Independent | Audit; Audit; Compensation; Nominating and Governance · Chair; Compensation; Nominating and Governance, chair | Source reportedE2 | |
| Chandler D. Robinson, MD MBA MSc | Not independent | None published | Source reportedE2 | |
| Christopher M. Starr, PhD | Independent | None published | Source reportedE2 | |
| Kim R. Tsuchimoto | Independent | None published | Source reportedE2 | |
| Lavina Talukdar, CFA | Independent | Audit; Audit; Compensation; Nominating and Governance; Compensation; Nominating and Governance | Source reportedE2 | |
| Raymond W. Anderson, MBA MS | Independent | Audit, chair; Audit · Chair; Compensation · Chair; Nominating and Governance; Compensation, chair; Nominating and Governance | Source reportedE2 |
Committees
12 claims| Committee | Chair | Members | Risks assigned | Evidence |
|---|---|---|---|---|
| Audit | Raymond W. Anderson, MBA MS | Raymond W. Anderson, MBA MS, Arthur J. Klausner, MBA, Lavina Talukdar, CFA | Not described in the published record | Source reportedE4 |
| Audit · Chair; Compensation · Chair; Nominating and Governance | Not published | Raymond W. Anderson, MBA MS | Not described in the published record | |
| Audit; Compensation; Nominating and Governance | Not published | Lavina Talukdar, CFA | Not described in the published record | |
| Audit; Compensation; Nominating and Governance · Chair | Not published | Arthur J. Klausner, MBA | Not described in the published record | |
| Compensation | Raymond W. Anderson, MBA MS | Raymond W. Anderson, MBA MS, Arthur J. Klausner, MBA, Lavina Talukdar, CFA | Not described in the published record | Source reportedE4 |
| Nominating and Governance | Arthur J. Klausner, MBA | Arthur J. Klausner, MBA, Lavina Talukdar, CFA, Raymond W. Anderson, MBA MS | Not described in the published record | Source reportedE4 |
| Fact | Stated value | Evidence |
|---|---|---|
| Committee appointment | Raymond W. Anderson, MBA MS: chair, Audit | Source reportedE4 |
| Committee appointment | Arthur J. Klausner, MBA: member, Audit | Source reportedE4 |
| Committee appointment | Lavina Talukdar, CFA: member, Audit | Source reportedE4 |
| Committee appointment | Raymond W. Anderson, MBA MS: chair, Compensation | Source reportedE4 |
| Committee appointment | Arthur J. Klausner, MBA: member, Compensation | Source reportedE4 |
| Committee appointment | Lavina Talukdar, CFA: member, Compensation | Source reportedE4 |
| Committee appointment | Arthur J. Klausner, MBA: chair, Nominating and Governance | Source reportedE4 |
| Committee appointment | Lavina Talukdar, CFA: member, Nominating and Governance | Source reportedE4 |
| Committee appointment | Raymond W. Anderson, MBA MS: member, Nominating and Governance | Source reportedE4 |
Financial context
1 claim| Fact | Stated value | Evidence |
|---|---|---|
| Security listing | MNPR (NASDAQ) | Source reportedE1 |
Other published claims
3 claims| Fact | Stated value | Evidence |
|---|---|---|
| Legal name | Monopar Therapeutics | Source reportedE1 |
| Entity status | Public listing published | Source reportedE1 |
| Published fact | US | Source reportedE1 |
Evidence
4 evidence records| Ref | Source | Authority | Source date | Retrieved | Rights | Cited by |
|---|---|---|---|---|---|---|
| E1 | Alpha canonical company public projectionCanonical identity | Open web | Not recorded | Rights not recorded, link only | 4 claims | |
| E2 | Monopar Therapeutics DEF 14A 2025-04-30SEC proxy | Authoritative, regulatory filing | Rights not recorded, link only | 6 claims | ||
| E3 | MNPR DEF 14A executive officersSEC filing | Authoritative, regulatory filing | Rights not recorded, link only | 1 claim | ||
| E4 | Auditboard_seats. Board seats | Authoritative, regulatory filing | Not recorded | Not recorded | Rights not recorded, link only | 12 claims |
No evidence record is pinned or signed yet.
Not yet in this record
These parts of a company record have no published claims yet. That is a coverage state, not a finding about the company. 1 further claim is under review.
- Control and voting
- Governance
- Risk
- AI oversight
- Legal
- Compensation
Index memberships
No current membership is published in Alpha's tracked index universe.
This is not evidence that the company is absent from every market index.
As of 22 Nov 2026. Rights-filtered public evidence only; no redistribution or model training is granted. Only source-backed memberships with an explicit public redistribution basis are returned.
Coverage states the record reports (12)
- Corporate structure
- Not reviewed. Parent, subsidiary and predecessor structure explains who is governed.
- Ownership
- Not reviewed. Ownership and voting power determine who can influence the board.
- Financials
- Not reviewed. Governance-relevant financial context frames capital and audit decisions.
- Compensation
- Not reviewed. Pay design shows how incentives are governed.
- Governance
- Not reviewed. Governing documents and provisions set the rules of the enterprise.
- Shareholder governance
- Not reviewed. Meeting and vote records show shareholder dissent and support.
- Audit
- Not reviewed. Auditor, controls and restatements show assurance over reporting.
- Legal
- Not reviewed. Material legal and regulatory matters show enforcement exposure.
- Risk
- Not reviewed. Risk ownership links the board, committees, executives and controls.
- Cyber
- Not reviewed. Cyber and data governance is a disclosed oversight domain.
- AI governance
- Not reviewed. AI oversight is a differentiated Alpha governance domain.
- Markets external
- Not reviewed. Auditors, advisors, investors and regulators form the external ecosystem.
Limits of this record (5)
- Absence of a leadership role, committee, or disclosure is not evidence that it does not exist.
- Only explicitly published canonical company identity and current confirmed public roles are included.
- Absence of a board, committee, executive, listing, or claim is not evidence that it does not exist.
- Public retrieval does not grant redistribution, model-training, direct-contact, or relationship-pathfinding rights.
- This Company Profile is an identity and evidence record, not an Alpha rating.
History
Version public-1Published .
- CEO role recorded. Chandler D. Robinson executive of Monopar Therapeutics, effective 30 Apr 2026.Effective . Recorded .
- Director appointed. Lavina Talukdar, CFA seat on Monopar Therapeutics, effective 2025.Effective . Recorded .
- Committee created. Audit; Compensation; Nominating and Governance committee of Monopar Therapeutics, effective 2025.Effective . Recorded .
- Committee member added. Lavina Talukdar, CFA member of Audit; Compensation; Nominating and Governance, effective 2025.Effective . Recorded .
- Director appointed. Kim R. Tsuchimoto seat on Monopar Therapeutics, effective 2023.Effective . Recorded .
- Director appointed. Arthur J. Klausner, MBA seat on Monopar Therapeutics, effective 2017.Effective . Recorded .
- Director appointed. Raymond W. Anderson, MBA MS seat on Monopar Therapeutics, effective 2017.Effective . Recorded .
- Committee created. Audit · Chair; Compensation · Chair; Nominating and Governance committee of Monopar Therapeutics, effective 2017.Effective . Recorded .
- Committee member added. Raymond W. Anderson, MBA MS member of Audit · Chair; Compensation · Chair; Nominating and Governance, effective 2017.Effective . Recorded .
- Committee created. Audit; Compensation; Nominating and Governance · Chair committee of Monopar Therapeutics, effective 2017.Effective . Recorded .
- Committee member added. Arthur J. Klausner, MBA member of Audit; Compensation; Nominating and Governance · Chair, effective 2017.Effective . Recorded .
- Director appointed. Chandler D. Robinson, MD MBA MSc seat on Monopar Therapeutics, effective 2014.Effective . Recorded .
- Director appointed. Christopher M. Starr, PhD seat on Monopar Therapeutics, effective 2014.Effective . Recorded .
About this record
- Alpha ID
- alpha:company:8816cde2-62f8-4a0c-8392-4fc559b683f2
- Version
- public-1:ro-d751713988987e9331980363e24189ce
- Identity
- Not claimed
- Evidence
- Source reported
- Evaluation
- Not assessed
- Monitoring
- Not monitored yet
- Authority
- Not published
- Freshness
- Current
- Integrity
- Not signed yet
- Basis
- Published company record built from public sources
- Never published
- Private company data: deployments, authority grants, TrustChecks, receipts, telemetry
The company can claim this record and correct or dispute any claim. Corrections are versioned and the original stays in history. A company's own statements are shown as its own and never replace the cited evidence.

